Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1314 participants
INTERVENTIONAL
2020-04-23
2021-04-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
NCT04647669
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
NCT07235020
101-PGC-005 for the Treatment of COVID-19
NCT05656521
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
NCT06800248
Safety and Efficacy of R0.6C Vaccine
NCT04862416
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LSoC
Local Standard of Care
No interventions assigned to this group
Rem+LSoC
Remdesivir with Local Standard of Care
Remdesivir
Two intravenous loading doses, then daily infusion for 10 days
HCQ+LSoC
Hydroxychloroquine with Local Standard of Care
Hydroxychloroquine
Two oral loading doses, then orally twice daily for 10 days
Lopi/Rito+LSoC
Lopinavir/Ritonavir with Local Standard of Care
Lopinavir / Ritonavir
Orally twice daily for 14 days
Lopi/Rito+IFN+LSoC
Lopinavir/Ritonavir and Interferon Beta 1a with Local Standard of Care
Lopinavir / Ritonavir
Orally twice daily for 14 days
Interferon beta-1a
Daily injection for 6 days
IFN+LSoC
Interferon Beta 1a with Local Standard of Care
Interferon beta-1a
Daily injection for 6 days
ACB+LSoC
Acalabrutinib with Local Standard of Care
Acalabrutinib
Orally twice daily for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remdesivir
Two intravenous loading doses, then daily infusion for 10 days
Hydroxychloroquine
Two oral loading doses, then orally twice daily for 10 days
Lopinavir / Ritonavir
Orally twice daily for 14 days
Interferon beta-1a
Daily injection for 6 days
Acalabrutinib
Orally twice daily for 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Probable or confirmed COVID-19 regardless of severity, i.e., mild, moderate and severe cases
2. Not already receiving any of the study drugs
3. Without known allergy or contraindications to any of the study drugs (in the view of the physician responsible for their care), and
4. Without anticipated transfer within 72 hours to a non-study hospital.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of the Philippines
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marissa Alejandria MD
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baguio General Hospital
Baguio City, Benguet, Philippines
Cebu Doctor's University Hospital
Cebu City, Cebu, Philippines
Perpetual Succor Hospital Cebu
Cebu City, Cebu, Philippines
Vicente Sotto Memorial Medical Center
Cebu City, Cebu, Philippines
Southern Philippines Medical Center
Davao City, Davao Region, Philippines
West Visayas University Medical Center
Iloilo City, Iloilo, Philippines
St Luke's Medical Center Global
City of Taguig, National Capital Region, Philippines
Makati Medical Center
Makati City, National Capital Region, Philippines
Chinese General Hospital
Manila, National Capital Region, Philippines
Manila Doctors Hospital
Manila, National Capital Region, Philippines
ManilaMed - Medical Center Philippines
Manila, National Capital Region, Philippines
San Lazaro Hospital
Manila, National Capital Region, Philippines
UP - Philippine General Hospital
Manila, National Capital Region, Philippines
Asian Hospital and Medical Center
Muntinlupa, National Capital Region, Philippines
Research Institute for Tropical Medicine
Muntinlupa, National Capital Region, Philippines
San Juan de Dios Educational Foundation Inc - Hospital
Pasay, National Capital Region, Philippines
The Medical City
Pasig, National Capital Region, Philippines
Diliman Doctors Hospital
Quezon City, National Capital Region, Philippines
Fe Del Mundo Medical Center
Quezon City, National Capital Region, Philippines
Lung Center of the Philippines
Quezon City, National Capital Region, Philippines
St Luke's Medical Center Quezon City
Quezon City, National Capital Region, Philippines
University of the East Ramon Magsaysay Memorial Medical Center
Quezon City, National Capital Region, Philippines
World Citi Medical Center
Quezon City, National Capital Region, Philippines
Cardinal Santos Medical Center
San Juan City, National Capital Region, Philippines
Batangas Medical Center
Batangas, , Philippines
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SJREB-2020-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.